Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director · CHIEF EXECUTIVE OFFICER | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2036-09-15 | Direct | 193,957 |
Reported balance
After 2026-09-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 193,957 · Balance 193,957 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 193,957 |
Reported balance
After 2026-09-15 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-09-15 · Grant · Acquired 193,957 · Balance 193,957 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 18, 2026 20:41 UTC Amendment | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 193,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001995275-26-000018 · form4a-09182026_080949.xml · derivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,957 Underlying: Common Stock · 193,957 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 20:41 UTC Amendment | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock option (right to buy) · Derivative | 193,957 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001995275-26-000018 · form4a-09182026_080949.xml · derivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,957 Underlying: Common Stock · 193,957 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:07 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 193,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001995275-26-000016 · form4-09152026_110953.xml · derivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,957 Underlying: Common Stock · 193,957 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:07 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock option (right to buy) · Derivative | 193,957 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001995275-26-000016 · form4-09152026_110953.xml · derivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,957 Underlying: Common Stock · 193,957 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:03 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantCommon Stock | 51,021 | $3.92 | $200,002.32 |
DisclosureSEC source: 0001995275-26-000014 · form4-05182026_080535.xml · nonDerivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 569,643 Read SEC document |
| April 09, 2026 Filed Apr 10, 2026 22:46 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 14,500 | $3.38 | $49,010.00 |
DisclosureSEC source: 0001995275-26-000012 · form4-04102026_100459.xml · nonDerivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518,622 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 08, 2026 Filed Apr 9, 2026 00:32 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 63,945 | $3.40 | $217,413.00 |
DisclosureSEC source: 0001995275-26-000008 · form4-04092026_120451.xml · nonDerivative · entry 3 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,122 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 00:32 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 94,087 | $3.43 | $322,718.41 |
DisclosureSEC source: 0001995275-26-000008 · form4-04092026_120451.xml · nonDerivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 597,067 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 06, 2026 Filed Apr 9, 2026 00:32 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 102,395 | $3.51 | $359,406.45 |
DisclosureSEC source: 0001995275-26-000008 · form4-04092026_120451.xml · nonDerivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 691,154 F1 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 22:17 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 26,858 | $3.48 | $93,465.84 |
DisclosureSEC source: 0001995275-26-000006 · form4-04032026_100411.xml · nonDerivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 793,549 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:17 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 831,148 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001995275-26-000006 · form4-04032026_100411.xml · derivative · entry 4 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,148 Underlying: Common Stock · 831,148 shares Expires 2036-04-01 F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:17 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionRestricted Stock Units · Derivative | 775,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001995275-26-000006 · form4-04032026_100411.xml · derivative · entry 3 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 775,828 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:17 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionCommon Stock | 775,828 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001995275-26-000006 · form4-04032026_100411.xml · nonDerivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 820,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 10, 2026 23:36 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | SaleCommon Stock | 5,100 | $3.31 | $16,878.96 |
DisclosureSEC source: 0001995275-26-000002 · form4-03102026_110350.xml · nonDerivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,579 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 01, 2026 Filed Mar 10, 2026 23:36 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionRestricted Stock Units · Derivative | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001995275-26-000002 · form4-03102026_110350.xml · derivative · entry 3 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 16,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document |
| March 01, 2026 Filed Mar 10, 2026 23:36 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | Exercise / conversionCommon Stock | 16,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001995275-26-000002 · form4-03102026_110350.xml · nonDerivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 23:22 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 775,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010076 · form4-04032025_110406.xml · derivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775,828 Underlying: Common Stock · 775,828 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 23:22 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 775,828 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001415889-25-010076 · form4-04032025_110406.xml · derivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775,828 Underlying: Common Stock · 775,828 shares Expires 2035-04-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 01:37 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 5,690 | $2.35 | $13,371.50 |
DisclosureSEC source: 0001415889-25-006316 · form4-03042025_010346.xml · nonDerivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,429 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 01:37 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | Exercise / conversionRestricted Stock Units · Derivative | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006316 · form4-03042025_010346.xml · derivative · entry 3 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 16,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 01:37 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | Exercise / conversionCommon Stock | 16,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-006316 · form4-03042025_010346.xml · nonDerivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. Read SEC document |
| October 03, 2024 Filed Oct 3, 2024 23:03 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 9,689 | $1.94 | $18,796.66 |
DisclosureSEC source: 0001415889-24-024676 · form4-10032024_111036.xml · nonDerivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,869 F2 · kind: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 23:03 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | Exercise / conversionRestricted Stock Units · Derivative | 32,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024676 · form4-10032024_111036.xml · derivative · entry 3 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to the award vested on October 2, 2024. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to the award vested on October 2, 2024. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 23:03 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | Exercise / conversionCommon Stock | 32,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024676 · form4-10032024_111036.xml · nonDerivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:15 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantRestricted Stock Units · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006414 · form4-03052024_120318.xml · derivative · entry 3 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. F4 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:15 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001415889-24-006414 · form4-03052024_120318.xml · derivative · entry 2 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2034-03-01 F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:15 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock option (right to buy) · Derivative | 30,768 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001415889-24-006414 · form4-03052024_120318.xml · derivative · entry 1 Lennon David James · CIK 0001995275 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,768 Underlying: Common Stock · 30,768 shares Expires 2034-03-01 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall be fully vested on the Grant Date, subject to such Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the Grant Date. "Grant Date" shall mean March 1, 2024. This option comprises a portion of the Reporting Person's bonus for 2023 performance. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 22:49 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 490,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051695 · doc4.xml · derivative · entry 2 Lennon David James · CIK 0001995275 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,000 Underlying: Common Stock · 490,000 shares Expires 2033-10-02 F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2023 Inducement Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest one (1) year after the Date of Grant, and one-forty-eighth (1/48th) of the shares subject to the option shall vest monthly thereafter on the same day of the month as the Date of Grant (and if there is no corresponding day, the last day of the month), such that the option will be fully vested and exercisable four (4) years from the Date of Grant. "Date of Grant" shall mean October 2, 2023. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 22:49 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantRestricted Stock Units · Derivative | 32,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051695 · doc4.xml · derivative · entry 1 Lennon David James · CIK 0001995275 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,558 Underlying: Common Stock · 32,558 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest on October 2, 2024. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest on October 2, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.